公开(公告)号：US11046683B2

公开(公告)日：2021-06-29

申请号：US16470196

申请日：2017-12-14

申请人： ONO PHARMACEUTICAL CO., LTD. ,  Vanderbilt University

发明人： Craig W Lindsley ,  Joshua M. Wieting ,  Kevin M. McGowan ,  Jerod S. Denton ,  Kentaro Yashiro ,  Haruto Kurata ,  Yoko Sekioka ,  Takahiro Mori ,  Yuzo Iwaki

IPC分类号： C07D471/04 ,  C07D257/04 ,  A61K31/41 ,  A61K31/4245 ,  A61K31/4353 ,  A61K31/4439 ,  A61K31/5375 ,  C07C255/57 ,  C07C317/28 ,  C07D209/30 ,  C07D213/89 ,  C07D231/56 ,  C07D235/16 ,  C07D237/24 ,  C07D239/47 ,  C07D249/08 ,  C07D249/18 ,  C07D265/36 ,  C07D271/10 ,  C07D285/14 ,  C07D295/04 ,  C07D401/04 ,  C07D513/04

摘要： Disclosed is a compound of formula (I): wherein all symbols are defined in the description. Also disclosed are pharmaceutical compositions comprising the compounds, methods of making the compounds, kits comprising the compounds, and methods of using the compounds, compositions and kits for treatment of disorders associated with TREK-1, TREK-2 or both TREK-1 and TREK-2 dysfunction in a mammal.

公开(公告)号：US11851428B2

公开(公告)日：2023-12-26

申请号：US17328814

申请日：2021-05-24

申请人： ONO PHARMACEUTICAL CO., LTD. ,  VANDERBILT UNIVERSITY

发明人： Craig W. Lindsley ,  Joshua M. Wieting ,  Kevin M. Mcgowan ,  Jerod S. Denton ,  Kentaro Yashiro ,  Haruto Kurata ,  Yoko Sekioka ,  Takahiro Mori ,  Yuzo Iwaki

IPC分类号： C07D213/36 ,  C07D231/12 ,  C07D249/08 ,  C07D401/04 ,  A61K31/454 ,  C07D471/04 ,  C07C255/57 ,  C07C317/28 ,  C07D209/30 ,  C07D213/89 ,  C07D231/56 ,  C07D235/16 ,  C07D237/24 ,  C07D239/47 ,  C07D249/18 ,  C07D257/04 ,  C07D265/36 ,  C07D271/10 ,  C07D285/14 ,  C07D295/04 ,  C07D513/04

CPC分类号： C07D471/04 ,  C07C255/57 ,  C07C317/28 ,  C07D209/30 ,  C07D213/89 ,  C07D231/56 ,  C07D235/16 ,  C07D237/24 ,  C07D239/47 ,  C07D249/08 ,  C07D249/18 ,  C07D257/04 ,  C07D265/36 ,  C07D271/10 ,  C07D285/14 ,  C07D295/04 ,  C07D401/04 ,  C07D513/04

摘要： Disclosed is a compound of formula (I):






wherein all symbols are defined in the description. Also disclosed are pharmaceutical compositions comprising the compounds, methods of making the compounds, kits comprising the compounds, and methods of using the compounds, compositions and kits for treatment of disorders associated with TREK-1, TREK-2 or both TREK-1 and TREK-2 dysfunction in a mammal.